Phio Pharmaceuticals Corp (NASDAQ: PHIO) is 26.67% higher on its value in year-to-date trading and has touched a low of $1.53 and a high of $10.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PHIO stock was last observed hovering at around $2.55 in the last trading session, with the day’s loss setting it -0.27%.
Currently trading at $2.28, the stock is -7.49% and -8.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.23 million and changing -10.59% at the moment leaves the stock -43.38% off its SMA200. PHIO registered -53.95% loss for a year compared to 6-month loss of -34.67%. The firm has a 50-day simple moving average (SMA 50) of $2.49076 and a 200-day simple moving average (SMA200) of $4.04679.
The stock witnessed a 9.09% gain in the last 1 month and extending the period to 3 months gives it a -21.65%, and is -0.44% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 19.17% over the week and 24.31% over the month.
Phio Pharmaceuticals Corp (PHIO) has around 9 employees, a market worth around $10.89M and $0.00M in sales. Distance from 52-week low is 49.02% and -77.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-150.00%).
8.0 institutions hold shares in Phio Pharmaceuticals Corp (PHIO), with institutional investors hold 3.17% of the company’s shares. The shares outstanding are 4.78M, and float is at 3.27M with Short Float at 17.32%. Institutions hold 3.02% of the Float.
Phio Pharmaceuticals Corp (PHIO) Insider Activity
The most recent transaction is an insider purchase by Bitterman Robert J, the company’s President & CEO. SEC filings show that Bitterman Robert J bought 1,000 shares of the company’s common stock on Jun 07 ’24 at a price of $0.74 per share for a total of $740.0. Following the purchase, the insider now owns 20990.0 shares.
Phio Pharmaceuticals Corp disclosed in a document filed with the SEC on Jun 06 ’24 that Bitterman Robert J (President & CEO) bought a total of 1,000 shares of the company’s common stock. The trade occurred on Jun 06 ’24 and was made at $0.75 per share for $750.0. Following the transaction, the insider now directly holds 19990.0 shares of the PHIO stock.
Still, SEC filings show that on Feb 26 ’24, Bitterman Robert J (President & CEO) acquired 2,500 shares at an average price of $0.91 for $2275.0. The insider now directly holds 18,990 shares of Phio Pharmaceuticals Corp (PHIO).
